Grifols closes deals across the pond. Spanish pharmaceutical company has reached a cooperation agreement for at least fifteen years Canadian Blood ServicesAccording to the Canadian National Authority in Responsible Health System in the field of blood, to accelerate the self-sufficiency of immunoglobulin (Ig) in the country, pharmacy through a statement.
This agreement, the first of these features, will ensure the use of Canadian plasma for the production of immunoglobulins in Canada, specifically aimed at meeting the needs of the thousands of patients in the North American country who depend on these treatments. Ig are essential plasma proteins for the treatment of immunodeficiency and a wide range of other diseases.
Under this agreement, Grifols will work with Canadian Blood Services to gradually increase the amount of Canadian plasma needed to supply 2.4 million grams of IG per year 2026, During the fifteen years of the validity of this renewable contract, the price of Immunoglobulin will be adjusted from Western market prices and subject to revision from time to time.
Grifols is confident that the production facilities in Montreal will start operating in two years and that the factory will be fully operational in 2026.
The collaboration agreement with Canadian Blood Services is part of Grifols’ long-term global growth strategy and complements the work Canadian Blood Services is already doing to accelerate its IG self-sufficiency levels. Canadian Blood Services intends to increase this by 15% to 50% in the country in the least amount of time.
Canada has a high rate of immunoglobulin consumption and currently needs to import up to 85% of its Ig. In addition, the demand for this protein keeps increasing on an average between 5% and 8% every year.
New production facilities in Montreal to start operating in 2024 And that the factory will be fully operational in 2026. Grifols will become the only large-scale commercial manufacturer of plasma products in Canada. Until then, production will take place at the Grifols facilities in Clayton (North Carolina, United States).
In 2020, Grifols acquired for over $400 million These production facilities in Montreal, which include a fractionation plant with a capacity of 1.5 million liters of plasma per year, and two purification plants. Since then, the company has been expanding and optimizing the features. The company also acquired its first plasma donation center in the country in the city of Winnipeg (Manitoba Province) in early 2022 as part of its commitment to Canada.
